Granulomatosis with polyangiitis induced by the anti-programmed cell death-1 inhibitor tislelizumab: A case report

doi:10.12998/wjcc.v13.i15.103239

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 15

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (228)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series.

Item

Count

PDF

HTML

103

Figures (1-4)

Sum=131

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=79

Publishing Process of This Article

Item

Count

Browse

Download

Sum=5

May 26, 2025 (publication date) through Jan 26, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. May 26, 2025; 13(15): 103239
Published online May 26, 2025. doi: 10.12998/wjcc.v13.i15.103239

Open in New Tab Full Size Figure Download Figure

Figure 1 Renal biopsy pathology. A: Large cellular crescent with peripheral inflammatory cell infiltration (periodic acid-Schiff 400 ×); B: Large cellular fibrous crescent (periodic acid-silver methenamine 400 ×).

Open in New Tab Full Size Figure Download Figure

Figure 2 Changes in the 24-hour urine output.

Open in New Tab Full Size Figure Download Figure

Figure 3 Renal function during the patient’s treatment. BUN: Blood urea nitrogen; SCR: Serum creatinine; UA: Uric acid.

Open in New Tab Full Size Figure Download Figure

Figure 4 Timeline for treatment and follow-up. ANCA: Anti-neutrophil cytoplasmic antibody; IV: Intravenous.

Citation: Zhao JH, Wang JJ, Li YW. Granulomatosis with polyangiitis induced by the anti-programmed cell death-1 inhibitor tislelizumab: A case report. World J Clin Cases 2025; 13(15): 103239
URL: https://www.wjgnet.com/2307-8960/full/v13/i15/103239.htm
DOI: https://dx.doi.org/10.12998/wjcc.v13.i15.103239